Search Results - "Naud, P"

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women by Paavonen, J, Prof, Naud, P, Prof, Salmerón, J, Prof, Wheeler, CM, Prof, Chow, S-N, Prof, Apter, D, MD, Kitchener, H, Prof, Castellsague, X, MD, Teixeira, JC, MD, Skinner, SR, PhD, Hedrick, J, MD, Jaisamrarn, U, MD, Limson, G, Prof, Garland, S, Prof, Szarewski, A, PhD, Romanowski, B, Prof, Aoki, FY, Prof, Schwarz, TF, Prof, Poppe, WAJ, Prof, Bosch, FX, MD, Jenkins, D, Prof, Hardt, K, PhD, Zahaf, T, PhD, Descamps, D, MD, Struyf, F, MD, Lehtinen, M, Prof, Dubin, G, MD

“…Summary Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic, generally well tolerated, and effective against HPV-16 or…”
Get full text

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women by De Carvalho, N, Teixeira, J, Roteli-Martins, C.M, Naud, P, De Borba, P, Zahaf, T, Sanchez, N, Schuind, A

“…Abstract We report efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years post-vaccination. The study was conducted in a…”
Get full text

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years by Romanowski, B, de Borba, P Colares, Naud, P S, Roteli-Martins, C M, De Carvalho, N S, Teixeira, J C, Aoki, F, Ramjattan, B, Shier, R M, Somani, R, Barbier, S, Blatter, M M, Chambers, C, Ferris, D, Gall, S A, Guerra, F A, Harper, D M, Hedrick, J A, Henry, D C, Korn, A P, Kroll, R, Moscicki, A-B, Rosenfeld, W D, Sullivan, B J, Thoming, C S, Tyring, S K, Wheeler, C M, Dubin, G, Schuind, A, Zahaf, T, Greenacre, Mary, Sgriobhadair, An

“…Prophylactic human papillomavirus (HPV) vaccines have to provide sustained protection. We assessed efficacy, immunogenicity, and safety of the HPV-16/18…”
Get full text

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18 by Szarewski, A., Poppe, W.A.J., Skinner, S.R., Wheeler, C.M., Paavonen, J., Naud, P., Salmeron, J., Chow, S.-N., Apter, D., Kitchener, H., Castellsagué, X., Teixeira, J.C., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Romanowski, B., Aoki, F.Y., Schwarz, T.F., Bosch, F.X., Harper, D.M., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., Dubin, G.

“…In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly…”
Get full text

Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression—Clinicopathological correlation by Hammes, Luciano S, Tekmal, Rajeshwar Rao, Naud, Paulo, Edelweiss, Maria Isabel, Kirma, Nameer, Valente, Philip T, Syrjänen, Kari J, Cunha-Filho, João Sabino

“…Abstract Objective To evaluate the population of macrophages during the cervical malignant transformation and its influence in CIN outcome. Methods Biopsies…”
Get full text

Clinical trials of cancer screening in the developing world and their impact on cancer healthcare by SANKARANARAYANAN, R, SAUVAGET, C, RAMADAS, K, NGOMA, T, TEGUETE, I, MUWONGE, R, NAUD, P, NESSA, A, KUHAPREMA, T, QIAO, Y

“…Several research and training initiatives were organized by the International Agency for Research on Cancer (IARC) in collaboration with national institutions…”
Get full text

Comparing PAP Smear Cytology, Aided Visual Inspection, Screening Colposcopy, Cervicography and HPV Testing as Optional Screening Tools in Latin America. Study Design and Baseline Data of the LAMS Study by Syrjänen, K, Naud, P, Derchain, S, Roteli-Martins, C, Longatto-Filho, A, Tatti, S, Branca, M, Erzen, M, Hammes, L S, Matos, J, Gontijo, R, Sarian, L, Braganca, J, Arlindo, F C, Maeda, M Y S, Lörincz, A, Dores, G B, Costa, S, Syrjänen, S

“…Objectives: This is a European Commission (EC)-funded ongoing study known as the LAMS (Latin American Screening) study, where PAP smear/liquid-based cytology…”
Get full text

Efficacy of the ASO4-adjuvanted HPV-16/18 vaccine in reduction of abnormal cytology, colposcopy referrals and cervical excision therapies: PATRICIA end-of-study results by Wheeler, C, Paavonen, J, Naud, P, Salmeron, J, Chow, S, Apter, D, Kitchener, H, Castellsagué, X, Teixeira, J

Get full text

Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3 by Syrjänen, K, Shabalova, I, Naud, P, Derchain, S, Sarian, L, Kozachenko, V, Zakharchenko, S, Roteli-Martins, C, Nerovjna, R, Longatto-Filho, A, Kljukina, L, Tatti, S, Branovskaja, M, Branca, M, Grunjberga, V, Erzen, M, Juschenko, A, Hammes, L Serpa, Costa, S, Podistov, J, Syrjänen, S

“…In addition to oncogenic 'high-risk' human papillomaviruses (HR-HPV), several co-factors are needed in cervical carcinogenesis, but it is poorly understood…”
Get more information

O929 Sustained levels of total and neutralising antibodies and favourable long term safety with the HPV-16/18 AS04-adjuvanted vaccine ( Cervarix ®): Follow-up to 7.3 years by De Carvalho, N, Roteli-Martins, C, Teixeira, J, Naud, P, De Borba, P, Zahaf, T, Sanchez, N, Schuind, A

Get full text

Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models by Syrjänen, K, Shabalova, I, Sarian, L, Naud, P, Longatto-Filho, A, Derchain, S, Kozachenko, V, Zakharchenko, S, Roteli-Martins, C, Nerovjna, R, Kljukina, L, Tatti, S, Branovskaja, M, Branca, M, Grunjberga, V, Erzen, M, Juschenko, A, Serpa Hammes, L, Podistov, J, Costa, S, Syrjänen, S

“…In addition to the oncogenic human papillomavirus (HPV), several cofactors are needed in cervical carcinogenesis, but whether the HPV covariates associated…”
Get more information

Risk estimates for persistent high-risk human papillomavirus infections as surrogate endpoints of progressive cervical disease critically depend on reference category: analysis of the combined prospective cohort of the New Independent States of the Former Soviet Union and Latin American Screening studies by Syrjänen, K, Shabalova, I, Naud, P, Kozachenko, V, Derchain, S, Zakharchenko, S, Roteli-Martins, C, Nerovjna, R, Longatto-Filho, A, Kljukina, L, Tatti, S, Branovskaja, M, Hammes, L S, Branca, M, Grunjberga, V, Eržen, M, Juschenko, A, Costa, S, Sarian, L, Podistov, J, Syrjänen, S

“…To make feasible future clinical trials with new-generation human papillomavirus (HPV) vaccines, novel virological surrogate endpoints of progressive disease…”
Get more information

L004 New insights into the mechanisms of the cardiac electrophysiological changes with aging in mice by Naud, P, Courboulin, A, Morissard, J, Frelin, Y, Demolombe, S

“…Introduction Age is the single biggest risk factor for the developing heart failure and other cardiac problems. With a large increase in the elderly population…”
Get full text

Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study by Longatto-Filho, A, Erzen, M, Branca, M, Roteli-Martins, C, Naud, P, Derchain, S F M, Hammes, L, Sarian, L O, Bragança, J F, Matos, J, Gontijo, R, Lima, T, Maeda, M Y S, Tatti, S, Syrjänen, S, Dores, G, Lörincz, A, Syrjänen, K

“…Hybrid capture II (HC II) test for oncogenic human papillomaviruses (HPV) was carried out in a cohort of 4284 women at their first clinical visit. Overall…”
Get more information

Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the NIS-LAMS cohort by Syrjänen, K, Shabalova, I, Sarian, L, Naud, P, Longatto-Filho, A, Derchain, S, Kozachenko, V, Zakharchenko, S, Roteli-Martins, C, Nerovjna, R, Kljukina, L, Tatti, S, Branovskaja, M, Branca, M, Grunjberga, V, Erzen, M, Juschenko, A, Hammes, L Serpa, Podistov, J, Costa, S, Syrjänen, S

“…The complex natural history of human papillomavirus (HPV) infections following a single HPV test can be modeled as competing-risks events (i.e., no-,…”
Get more information

Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil by Naud, P., Matos, J., Hammes, L., Stuckzynski, J., Brouwers, K., Magno, V., Dias, E., Crusius, P., d’Avila, A., Campos, C., Costa, M., Höblik, M., Marc, C., Marroni, R., Syrjänen, K.

“…To explore the predictors of intermediate endpoints of cervical cancer in 500 women living in Porto Alegre. Five hundred randomly selected women (mean age 20.3…”
Get full text

Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS study by Longatto-Filho, A, Roteli-Martins, C, Hammes, L, Etlinger, D, Pereira, S M Miranda, Erzen, M, Branca, M, Naud, P, Derchain, S F M, Sarian, L O, Matos, J, Gontijo, R, Lima, T, Maeda, M Y S, Tatti, S, Syrjänen, S, Syrjänen, K

“…To compare Hybrid Capture II (HC2) in detecting high-risk (HR) HPV in patient-collected vaginal samples with those obtained using gynaecologist collected…”
Get more information

Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohort by Syrjänen, K, Naud, P, Derchain, S, Roteli-Martins, C, Longatto-Filho, A, Tatti, S, Branca, M, Erzen, M, Hammes, L S, Matos, J, Gontijo, R, Sarian, L, Bragança, J, Arlindo, F C, Maeda, M Y S, Lörincz, A, Dores, G B, Costa, S, Syrjänen, S

“…Drug abuse (addiction) has been listed among the risk factors for human papillomavirus (HPV) infections, but no case-control studies exist to rule out sexual…”
Get more information

Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study by Derchain, S F, Sarian, L O, Naud, P, Roteli-Martins, C, Longatto-Filho, A, Tatti, S, Branca, M, Erzen, M, Serpa-Hammes, L, Matos, J, Gontijo, R C, Bragança, J F, Lima, T P, Maeda, M Y S, Lörincz, A, Dores, G B, Costa, S, Syrjänen, S, Syrjänen, K

“…To assess whether human papillomavirus (HPV) testing is a safe enough approach to warrant extension of the screening intervals of baseline Papanicolaou…”
Get more information

Microwave characterization of magnetic materials under uniaxial and biaxial mechanical compressive stress by Maze-Merceur, G., Naud, P.

“…A new technique of determining the permittivity and the permeability of ferrite material from microwave measurements in a rectangular waveguide under biaxial…”
Get full text